c4c

conect4children - Collaborative network for European clinical trials for children
c4c logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 10
Grant agreement number
777389

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
67 000 000
EFPIA in kind
73 496 816
Total Cost
140 496 816

Summary

Less than half of all authorised medicines commonly used in children have been properly tested in this group, and running clinical trials involving children is hard. The conect4children (c4c) project aims to create a sustainable, integrated pan-European collaborative paediatric network that will speed up and facilitate the running of high quality clinical trials in children while ensuring that the voices of young patients and their families are heard. It will build the capacity for conducting multinational paediatric clinical trials for all disease areas and all phases of the clinical drug development process. One focus of the project is to promote innovative trial designs that will support drug development for rare paediatric diseases and areas of high medical need. The project will also set up an education and training platform for future leaders in paediatric drug development. Ultimately, the paediatric clinical trials network will contribute to the development of better medicines for babies, children and young people.

Achievements & News

c4c announces first studies on medicines in children
May 2019

The c4c project has announced its first studies designed to increase our understanding of certain medicines that are common used in babies, children and young people. Currently half of all medicines used in children have never actually been tested in children; c4c is working to change this by creating a pan-European network for paediatric clinical trials. The project has now selected four studies that will leverage the fledgling network and implement new ways to integrate children’s and young people’s views in clinical trial design. They will also apply novel ways of evaluating medicines. The four studies address a range of disease areas and age groups. One will assess the effectiveness of paracetamol in premature babies with a serious heart defect called patent ductus arteriosus. Another will investigate the use of steroids in children with Kawasaki disease, which mainly affects the under 5’s and is characterised by a high temperature, rash, swollen glands in the neck, dry, cracked lips, and red eyes, fingers or toes. The third study focuses on posaconazole in children and young people with cystic fibrosis and an Aspergillus (fungal) infection. Finally, the project will run a trial on losartan in children and youngsters with osteogenesis imperfecta, a genetic disorder which results in fragile bones. All four studies will be led by academic institutions. Additional studies led by industry partners are also planned.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Institut De Recherches Internationales Servier, Suresnes, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Aristotelio Panepistimio Thessalonikis, Thessaloniki, Greece
  • Arsenal.It - Centro Veneto Ricercae Innovazione Per La Sanita Digitale, Treviso Tv, Italy
  • Associação para Investigação e Desenvolvimento da Faculdade de Medicina, Lisbon, Portugal
  • Ecnp Research And Scholarship Stichting (De Ecnp Research And Scholarship Foundation), Utrecht, Netherlands
  • Ecrin European Clinical Research Infrastructure Network, Paris, France
  • European Cystic Fibrosis Society, Karup, Denmark
  • Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy
  • Fondazione Per La Ricerca Farmacologica Gianni Benzi Onlus, Valenzano Bari, Italy
  • Gyermekgyogyaszati Klinikai Vizsgaloi Halozat, Budapest, Hungary
  • Helse Bergen Hf*Haukeland University Hospital, Bergen, Norway
  • Helsingin Ja Uudenmaan Sairaanhoitopiirin Kuntayhtymä, Helsinki, Finland
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Instytut Pomnik Centrum Zdrowia Dziecka, Warszawa, Poland
  • Istituto Giannina Gaslini, Genova, Italy
  • Karolinska Institutet, Stockholm, Sweden
  • Ospedale Pediatrico Bambino Gesu, Rome, Italy
  • Robert Bosch Gesellschaft Fur Medizinische Forschung Mbh, Stuttgart, Germany
  • Servizo Galego De Saude, Santiago de Compostela, Spain
  • Siop Europe Asbl, Brussels, Belgium
  • Stichting Katholieke Universiteit, Nijmegen, Netherlands
  • Swiss Clinical Trial Organisation, Basel, Switzerland
  • Tartu Ulikool, Tartu, Estonia
  • The University Of Liverpool, Liverpool, United Kingdom
  • Universitaetsklinikum Heidelberg, Heidelberg, Germany
  • Universiteit Gent, Gent, Belgium
  • University College Cork - National University Of Ireland, Cork, Cork, Ireland
  • University College London, London, United Kingdom
  • University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
  • Univerzita Karlova, Prague 1, Czech Republic
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Okids GMBH, Wien, Austria
Patient organisations
  • Eurordis - European Organisation For Rare Diseases Association, Paris, France
  • Fundacio Sant Joan De Deu, Esplugues de Llobregat, Spain
Third parties
  • Consorzio Per Valutazioni Biologiche E Farmacologiche, Pavia, Italy
  • Mmi Clinical Research Development Ireland, Dublin, Ireland
  • Stockholms Lans Landsting, Stockholm, Sweden
  • Universita Degli Studi Di Roma Tor Vergata, Rome, Italy
Non EFPIA companies
  • Helios Dr. Horst Schmidt Kliniken Wiesbaden GMBH, Wiesbaden, Germany

CONTACT

Project coordinator
Carlo GIAQUINTO
FONDAZIONE PENTA-FOR THE TREATMENT AND CARE OF CHILDREN WITH HIV-ONLUS
carlo.giaquinto[at]unipd.it